Al­lo­gene wins a ma­jor re­prieve for its lead­ing off-the-shelf cell ther­a­py pipeline

Al­lo­gene is rolling in­to JP Mor­gan week with a big win for its de­vel­op­ment cam­paign for off-the-shelf CAR-Ts. Late last week the FDA agreed to lift the reg­u­la­to­ry block­ade that had been dropped on their full set of clin­i­cal tri­als af­ter ev­i­dence of chro­mo­so­mal changes in one of the pa­tients trig­gered a safe­ty alert.

In an ad­vance of the an­nounce­ment Mon­day morn­ing, Al­lo­gene $AL­LO CEO David Chang said in an in­ter­view that the com­pa­ny worked through the last 3 months with reg­u­la­tors to ze­ro in on the ex­act trig­ger of the chro­mo­so­mal mu­ta­tions. Reg­u­la­tors, he said, agreed that the drug wasn’t in­volved and re­leased the clin­i­cal hold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER